These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8041200

  • 1. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casaldáliga J, Díaz de Heredia C, Olivé T, Bastida P.
    Med Clin (Barc); 1994 May 21; 102(19):721-4. PubMed ID: 8041200
    [Abstract] [Full Text] [Related]

  • 2. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct 21; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 3. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb 21; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 4. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Feb 21; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW.
    N Engl J Med; 1994 Sep 01; 331(9):567-73. PubMed ID: 8047080
    [Abstract] [Full Text] [Related]

  • 6. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug 01; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 7. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Aug 01; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 8. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Aug 01; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 9. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 01; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 10. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
    Albo C, Cabrera J, Dios A, Castro M, Ares C, Constenla I, López D.
    Sangre (Barc); 1995 Dec 01; 40(6):441-5. PubMed ID: 8850225
    [Abstract] [Full Text] [Related]

  • 11. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct 01; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 12. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G.
    Haematologica; 1991 Oct 01; 76(2):131-4. PubMed ID: 1937171
    [Abstract] [Full Text] [Related]

  • 13. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M.
    Acta Otorhinolaryngol Belg; 2004 Oct 01; 58(2):113-7. PubMed ID: 15515654
    [Abstract] [Full Text] [Related]

  • 14. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L, Gurrado R, Zecchino C, Manolo F, De Sanctis V, Cisternino M, Caruso-Nicoletti M, Galati M.
    J Pediatr Endocrinol Metab; 1998 Oct 01; 11 Suppl 3():845-9. PubMed ID: 10091155
    [Abstract] [Full Text] [Related]

  • 15. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
    Viprakasit V, Tanphaichitr VS, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G, Kankirawatana S, Pung-Amritt P, Suvatte V.
    J Med Assoc Thai; 2001 Jul 01; 84(7):929-41. PubMed ID: 11759973
    [Abstract] [Full Text] [Related]

  • 16. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.
    Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ.
    N Engl J Med; 1990 Sep 13; 323(11):713-9. PubMed ID: 2388669
    [Abstract] [Full Text] [Related]

  • 17. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study].
    Cario H, Stahnke K, Kohne E.
    Klin Padiatr; 1999 Sep 13; 211(6):431-7. PubMed ID: 10592921
    [Abstract] [Full Text] [Related]

  • 18. Spermatogenesis in young adult patients with beta-thalassaemia major long-term treated with desferrioxamine.
    De Sanctis V, Borsari G, Brachi S, Govoni M, Carandina G.
    Georgian Med News; 2008 Mar 13; (156):74-7. PubMed ID: 18403814
    [Abstract] [Full Text] [Related]

  • 19. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug 13; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 20. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
    Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR.
    Pediatr Endocrinol Rev; 2004 Dec 13; 2 Suppl 2():285-91. PubMed ID: 16462713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.